Michael Platten

Michael Platten is an expert in Neurology at University Medical Centre Mannheim (Germany). As of September 2026, ScienceLeadR ranks Michael Platten in the top 1% of experts worldwide for Glioma, Brain Neoplasms and Nervous System Neoplasms. Michael Platten has authored 586 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 2 of them ongoing. SLR score: 2,160 (community average: 125). How the SLR is computed.

Neurology

Subspecialties: Oncology - Immunology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on September 9, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Top Autoimmune Diseases key opinion leaders

Organizations

Career arc: 2000 - 2026

Source: PubMed

Heidelberg University (Germany)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 586

Citations

Citations: 41 263 1st author: 57 Last author: 103 Unique author: 9

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Type I interferon drives T cell responses to amyloid beta in the central nervous system. PMID 42026067 — cells, amyloid beta-peptides, biological science disciplines, pathology, central nervous system, immunity, interferon type i, amyloid, nervous system, t-lymphocytes	Nat Commun	2026
Functional segregation of HIF-1α and AhR controls NK cell responsiveness under hypoxia. PMID 42006290 — cells, killer cells, natural, hypoxia	iScience	2026
Cancer neuroscience: The past, the present, and the road ahead. PMID 41997131 — neoplasms, cell biology, neurosciences, therapeutics, nervous system	Cell Top journal	2026
Association of Preferred Language and Race with Perioperative Oral Midazolam Administration in Pediatric Patients: A Retrospective Cohort Study. PMID 41979789 — language, cohort studies, midazolam	J Racial Ethn Health Disparities	2026
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial. PMID 41951573 — radiotherapy, biological science disciplines, neoplasms, bevacizumab, glioblastoma, therapeutics, rna	Nat Commun	2026

Clinical Studies 14

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 6

Phase 1 4

Phase 1/Phase 2 2

Phase 2 1

Phase 4 1

By status:

Completed 8

Active not recruiting 4

Recruiting 2

By type:

Interventional 14

By Monocentric/Multicentric:

monocentric 3

multicentric2to4 0

multicentric5to9 2

multicentricup10 9

Main Topics

Nervous System Diseases 4

Immune System Diseases 2

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas) NCT05331521 — radiotherapy, brain neoplasms, quality of life, glioma, bone marrow, temozolomide, brain, neoplasms, lomustine, recycling, drug therapy, chemoradiotherapy, vincristine, diagnosis, procarbazine, therapeutics, oligodendroglioma, chemotherapy	Phase 3	Recruiting	2021
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3 Mutated Gliomas NCT04808245 — radiotherapy, injections, skin, cells, imiquimod, glioma, vaccines, immunotherapy, vaccination, histones, glioblastoma, therapeutics, protein subunit vaccines	Phase 1	Active not recruiting	2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice